GlassScriptPhysician profile
Manoj K Jain
NPI 1871559856
$711.05
in general payments reported to CMS, 2019-2025
11 companies · $116 in 2025
The $116 reported for 2025 was more than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.40 · 2020: $29.90 · 2021: $81.51 · 2022: $85.84 · 2023: $122 · 2024: $263 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $201.76 | 2021-2025 | Rybrevant, Erleada, Akeega |
| Beigene USA, INC. | $122.32 | 2023-2024 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $96.49 | 2020-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $75.98 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $71.84 | 2019-2022 | |
| Seagen INC. | $59.87 | 2022-2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $24.28 | 2024 | Enhertu |
| Beone Medicines USA, INC. | $23.00 | 2025 | Tevimbra |
| Servier Pharmaceuticals LLC | $18.64 | 2021 | |
| Abbvie INC. | $16.87 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,200.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.